R. Borson

907 total citations · 1 hit paper
7 papers, 682 citations indexed

About

R. Borson is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Hematology. According to data from OpenAlex, R. Borson has authored 7 papers receiving a total of 682 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 4 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Hematology. Recurrent topics in R. Borson's work include HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Breast Cancer Treatment Studies (2 papers). R. Borson is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Breast Cancer Treatment Studies (2 papers). R. Borson collaborates with scholars based in United States and India. R. Borson's co-authors include Barbara Klencke, Hope S. Rugo, Howard A. Burris, Svetislava J. Vukelja, Steven Limentani, Joyce O’Shaughnessy, Elizabeth Tan-Chiu, Sandhya Girish, Yu-Waye Chu and Lukas C. Amler and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and American Journal of Hematology.

In The Last Decade

R. Borson

7 papers receiving 660 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

2010 568 citations Howard A. Burris, Hope S. Rugo et al. Journal of Clinical Oncology profile →

Peers

R. Borson

ONCOL

RNMI

MB

PRM

GENET

S. D. Rubin United States

Sara García‐Alonso Spain

Kaori Fujimoto-Ouchi United States

Lisa M. Garrett United States

Ronald Shazer United States

Preeti Trisal United States

Jeff Sperinde United States

H. A. Burris United States

Jill J.J. Geenen Netherlands

Heather Kostner United States

S. D. Rubin United States

R. Borson

559 ×1.0

ONCOL

180 ×0.4

RNMI

191 ×1.6

MB

264 ×2.7

PRM

123 ×2.1

GENET

Citations per year, relative to R. Borson R. Borson (= 1×) peers S. D. Rubin

Countries citing papers authored by R. Borson

Since Specialization

Citations

This map shows the geographic impact of R. Borson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Borson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Borson more than expected).

Fields of papers citing papers by R. Borson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Borson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Borson. The network helps show where R. Borson may publish in the future.

Co-authorship network of co-authors of R. Borson

This figure shows the co-authorship network connecting the top 25 collaborators of R. Borson. A scholar is included among the top collaborators of R. Borson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Borson. R. Borson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Borson, R., Graydon Harker, James A. Reeves, et al.. (2012). Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer. 12(5). 322–330. 7 indexed citations

2.

Burris, Howard A., Hope S. Rugo, Svetislava J. Vukelja, et al.. (2010). Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy. Journal of Clinical Oncology. 29(4). 398–405. 568 indexed citations breakdown →

3.

Vogel, C. L., Howard A. Burris, Steven Limentani, et al.. (2009). A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results. Journal of Clinical Oncology. 27(15_suppl). 1017–1017. 50 indexed citations

4.

Vukelja, S., Hope S. Rugo, C Vogel, et al.. (2009). A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer.. Cancer Research. 69(2_Supplement). 33–33. 20 indexed citations

5.

Dunphy, Cherie H., et al.. (1999). Primary Mediastinal Large Cell Lymphoma with Sclerosis Containing a Large Number of T Cells. Applied Immunohistochemistry. 7(1). 48–51. 1 indexed citations

6.

Cohen, Lewis, Nancy B. McWilliams, William H. Zinkham, et al.. (1995). Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: A summary of case reports. American Journal of Hematology. 50(4). 269–276. 32 indexed citations

7.

Brown, R, et al.. (1994). Retained Hickman catheter cuff as an infection source following allogeneic bone marrow transplant.. PubMed. 14(1). 169–71. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact